行業(yè)新聞
當(dāng)前位置：首頁 > 關(guān)于三濟(jì) > 行業(yè)新聞
羅氏斥資4.5億美金收購(gòu)IQuum 進(jìn)軍分子診斷POCT市場(chǎng)
時(shí)間：2014-04-09 09:35:55 來源：轉(zhuǎn)化醫(yī)學(xué)網(wǎng) 點(diǎn)擊：
羅氏（Roche）4月7日宣布，耗資4.5億美元收購(gòu)IQuum公司。IQuum位于美國(guó)馬薩諸塞州，專注于開發(fā)護(hù)理現(xiàn)場(chǎng)（point-of-care，POC）產(chǎn)品，用于分子診斷市場(chǎng)。根據(jù)協(xié)議條款，羅氏將支付IQuum股東2.75億前期付款，以及1.75億美元的產(chǎn)品相關(guān)里程碑或然付款。該筆交易一旦完成，IQuum將被整合入羅氏分子診斷（Roche Molecular Diagnostics）。此次收購(gòu)，將使羅氏快速進(jìn)入分子診斷的護(hù)理現(xiàn)場(chǎng)（POC）細(xì)分市場(chǎng)。
羅氏將獲得IQuum公司的Liat系統(tǒng)（Laboratory-in-a-tube，管中實(shí)驗(yàn)室），該系統(tǒng)能夠以最少的培訓(xùn)，使護(hù)理人員在更接近患者的護(hù)理現(xiàn)場(chǎng)，開展快速的分子診斷測(cè)試。Liat分析器和Liat流感A/B試劑盒是利用Liat系統(tǒng)開發(fā)的首個(gè)產(chǎn)品，可提供與實(shí)驗(yàn)室檢測(cè)相媲美的可靠和準(zhǔn)確診斷結(jié)果，目前該產(chǎn)品已獲CE標(biāo)志并獲FDA批準(zhǔn)。
羅氏診斷首席運(yùn)營(yíng)官Roland Diggelmann稱，隨著IQuum的收購(gòu)，羅氏將利用服務(wù)于POC細(xì)分市場(chǎng)的尖端技術(shù)和產(chǎn)品進(jìn)一步增強(qiáng)自身的分子診斷部門?；颊邔默F(xiàn)場(chǎng)（on-the-spot）的準(zhǔn)確診斷中受益，這種診斷技術(shù)使得醫(yī)療保健專業(yè)人員能夠在靈活的環(huán)境下做出快速、知情的治療決策。
關(guān)于IQuum：
IQuum是開發(fā)管中實(shí)驗(yàn)室（lab-in-a-tube）技術(shù)的領(lǐng)導(dǎo)者，這是一種新穎的生物樣品檢測(cè)平臺(tái)，有望對(duì)生物檢測(cè)市場(chǎng)提供變革性的利益。該技術(shù)，能夠使非專業(yè)人員在任何環(huán)境下開展更快速和更復(fù)雜的生物樣本測(cè)試。
關(guān)于POCT：
POCT（Point of Care Testing，護(hù)理現(xiàn)場(chǎng)檢驗(yàn)）是一種嶄新的移動(dòng)檢驗(yàn)?zāi)Ｊ?，不僅專業(yè)醫(yī)護(hù)人員，經(jīng)過簡(jiǎn)單培訓(xùn)的患者及家屬也能獨(dú)立完成并能獲得有助于臨床診斷的信息。POCT不僅快速而且是現(xiàn)場(chǎng)分析，是其他檢驗(yàn)方法無法實(shí)現(xiàn)的。（轉(zhuǎn)化醫(yī)學(xué)網(wǎng)360zhyx.com）
英文原文：
Roche acquires IQuum to strengthen offerings in molecular diagnostics
IQuum’s unique products will allow Roche to quickly enter the point of care segment of molecular diagnostics
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the acquisition of IQuum, Inc. (IQuum) based in Marlborough, Massachusetts, USA. IQuum is a privately held company focused on developing point of care offerings for the molecular diagnostics market. Under the terms of the agreement, Roche will pay IQuum shareholders USD 275 million upfront and up to USD 175 million in contingent product related milestones. The transaction is subject to customary closing conditions.
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the acquisition of IQuum, Inc. (IQuum) based in Marlborough, Massachusetts, USA. IQuum is a privately held company focused on developing point of care offerings for the molecular diagnostics market. Under the terms of the agreement, Roche will pay IQuum shareholders USD 275 million upfront and up to USD 175 million in contingent product related milestones. The transaction is subject to customary closing conditions.
The acquisition will provide Roche with access to IQuum’s Laboratory-in-a-tube (Liat™) System, which enables healthcare workers to perform rapid molecular diagnostic testing in a point of care setting, closer to patients and with minimal training. The Liat™ Analyzer and Liat™ Influenza A/B Assay, the first test available for use on the system, produce reliable and accurate lab-like results and are CE marked and FDA cleared.
“With IQuum, we further strengthen our molecular diagnostics offerings with cutting-edge technology and products that serve the point of care segment. Patients will benefit from on-the-spot and accurate diagnoses, which will allow healthcare professionals to make rapid, informed treatment decisions in flexible settings,” said Roland Diggelmann, COO of Roche Diagnostics. “We welcome IQuum’s employees, who will continue to focus on the development and manufacturing of the Liat™ Analyzer and assays.”
“We are very excited to continue developing innovative molecular diagnostics solutions as part of the Roche Molecular Diagnostics team,” said Shuqi Chen, Ph.D., CEO and founder of IQuum. “Roche is the ideal company to deliver on the promise of our point of care molecular diagnostics technology. We are fully committed to the continued success of IQuum’s employees, products and pipeline.”
Once the transaction is complete, IQuum will be integrated into Roche Molecular Diagnostics.
About IQuum
IQuum is the leader in developing the lab-in-a-tube technology, a novel biological sample testing platform which provides revolutionary benefits to a broad cross section of the bioassay market. The Company's proprietary technology enables non-specialized personnel to perform more sophisticated biological sample testing in any setting with greater speed. Founded in 1998 by Dr. Shuqi Chen and his co-founder Keith Greenfield, the Company is commercializing its lab-in-a-tube technology and products for the clinical diagnostics, bio-defense, and industrial testing markets.
